Related Experiment Video
Updated: May 8, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV
Paul A Wender1,2, Clayton T Hardman3, Stephen Ho3
1Department of Chemistry, Stanford University, Stanford, CA 94305, USA. wenderp@stanford.edu.
Abstract:
Bryostatin 1 is an exceedingly scarce marine-derived natural product that is in clinical development directed at HIV/AIDS eradication, cancer immunotherapy, and the treatment of Alzheimer's disease. Despite this unique portfolio of indications, its availability has been limited and variable, thus impeding research and clinical studies. Here, we report a total synthesis of bryostatin 1 that proceeds in 29 total steps (19 in the longest linear sequence, >80% average yield per step), collectively produces grams of material, and can be scaled to meet clinical needs (~20 grams per year). This practical solution to the bryostatin supply problem also opens broad, facile, and efficient access to derivatives and potentially superior analogs.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis

